Can a medicine help in curing viral infection

A Phase IIB open label randomized controlled trial to evaluate the efficacy and safety of Ivermectin in reducing viral loads in patients with hematological disorders who are admitted with COVID 19 infection - Not applicable

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/05/025068

Enrollment

Registered

2020-05-07

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B338- Other specified viral diseases

Interventions

Intervention1: Ivermectin: The doses are as follows (based on body weight) 15 - 24 kg: 3 mg PO once 25 - 35 kg: 6 mg PO once 36 - 50 kg: 9 mg PO once 51 - 65 kg: 12 mg PO once 66 - 79 kg: 15 mg PO onc

Eligibility

Inclusion criteria

Inclusion criteria: Confirmed diagnosis of COVID19 infection based on +ve RTPCR

Exclusion criteria

Exclusion criteria: Patients with other viral infections

Design outcomes

Primary

Measure	Time frame
To study if Ivermectin can reduce the viral load in patients with hematological illnesses who are admitted with COVD19 infectionTimepoint: Day 7	—

Secondary

Measure	Time frame
To study the factors that affect viral load reduction To study if the reduction in viral load correlates with improvement in inflammatory parameters To study the incidence of serious adverse events and safety of this drug when used in hematological illnessesTimepoint: Day 7 Day 20	—

Countries

India

Contacts

Public ContactBiju George

Christian Medical College Vellore

biju@cmcvellore.ac.in04162282352

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026